Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt’s Lymphoma or Burkitt’s Leukemia
Study Information
Alliance Study ID: CALGB-10002
NCT Study ID (ClinicalTrials.gov): NCT00039130
Alliance Committee: Leukemia
Disease or Cancer Type: Leukemia & Myelodysplastic Syndromes (MDS), Lymphoma
Alliance Study Chair: David Rizzieri, MD
Status: COMPLETED
Study Description
RATIONALE: Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the numbers of immune cells found in bone marrow or peripheral blood and may help a person’s immune system recover from the side effects of chemotherapy. Combining chemotherapy with rituximab and filgrastim may kill more cancer cells.
PURPOSE: Phase II trial to study the effectiveness of combining rituximab with chemotherapy and filgrastim in treating patients who have Burkitt’s lymphoma or Burkitt’s leukemia.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information